{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:40:44Z","timestamp":1793292044364,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":1111,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1111\/ajt.15480","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:05:15Z","timestamp":1559361915000},"page":"3018-3034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":152,"title":["Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study"],"prefix":"10.1016","volume":"19","author":[{"given":"Stefan P.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-323X","authenticated-orcid":false,"given":"Helio","family":"Tedesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Chadban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamkant","family":"Mulgaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Cruzado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Watarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-2948","authenticated-orcid":false,"given":"Christophe","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Citterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titte R.","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6701-4680","authenticated-orcid":false,"given":"Flavio","family":"Vincenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pilar Hernandez","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1111\/ajt.15480_bib1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1600-6143.2011.03504.x","article-title":"Chronic calcineurin inhibitor nephrotoxicity-lest we forget","volume":"11","author":"Chapman","year":"2011","journal-title":"Am J Transplant."},{"issue":"6","key":"10.1111\/ajt.15480_bib2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1159\/000351648","article-title":"Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence","volume":"37","author":"Issa","year":"2013","journal-title":"Am J Nephrol."},{"issue":"3","key":"10.1111\/ajt.15480_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ckj\/sfx122","article-title":"Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network","volume":"11","author":"Sprangers","year":"2018","journal-title":"Clin Kidney J."},{"issue":"4","key":"10.1111\/ajt.15480_bib4","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.qco.0000172698.52408.be","article-title":"Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens","volume":"18","author":"Singh","year":"2005","journal-title":"Curr Opin Infect Dis."},{"issue":"6719","key":"10.1111\/ajt.15480_bib5","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature."},{"issue":"3","key":"10.1111\/ajt.15480_bib6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.TP.0000081399.75231.3B","article-title":"Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression","volume":"76","author":"Maluccio","year":"2003","journal-title":"Transplantation."},{"issue":"Suppl 2","key":"10.1111\/ajt.15480_bib7","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.2215\/CJN.02900707","article-title":"Viral infection after renal transplantation: surveillance and management","volume":"3","author":"Weikert","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"10.1111\/ajt.15480_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/ndt\/gfr306","article-title":"Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies","volume":"27","author":"Erdbruegger","year":"2012","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"10.1111\/ajt.15480_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1523-1755.2004.00735.x","article-title":"Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival","volume":"66","author":"Sagedal","year":"2004","journal-title":"Kidney Int."},{"issue":"6","key":"10.1111\/ajt.15480_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/17512433.2018.1479638","article-title":"Tailoring tacrolimus therapy in kidney transplantation","volume":"11","author":"Jouve","year":"2018","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"1","key":"10.1111\/ajt.15480_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.trre.2015.09.001","article-title":"Everolimus immunosuppression in kidney transplantation: what is the optimal strategy?","volume":"30","author":"Witzke","year":"2016","journal-title":"Transplant Rev (Orlando)."},{"issue":"25","key":"10.1111\/ajt.15480_bib12","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1111\/ajt.15480_bib13","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","article-title":"Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation","volume":"9","author":"Ekberg","year":"2009","journal-title":"Am J Transplant."},{"issue":"6","key":"10.1111\/ajt.15480_bib14","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant."},{"issue":"7","key":"10.1111\/ajt.15480_bib15","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation."},{"issue":"5","key":"10.1111\/ajt.15480_bib16","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl Int."},{"issue":"5","key":"10.1111\/ajt.15480_bib17","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data","volume":"17","author":"Qazi","year":"2017","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.15480_bib18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/TP.0b013e31824810e6","article-title":"Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients","volume":"93","author":"Nashan","year":"2012","journal-title":"Transplantation."},{"issue":"11","key":"10.1111\/ajt.15480_bib19","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2011.03674.x","article-title":"Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials","volume":"11","author":"Brennan","year":"2011","journal-title":"Am J Transplant."},{"issue":"9","key":"10.1111\/ajt.15480_bib20","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/ajt.14215","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus","volume":"17","author":"Shihab","year":"2017","journal-title":"Am J Transplant."},{"issue":"8","key":"10.1111\/ajt.15480_bib21","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2215\/CJN.13221216","article-title":"CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials","volume":"12","author":"Mallat","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"10.1111\/ajt.15480_bib22","doi-asserted-by":"crossref","first-page":"e12846","DOI":"10.1111\/tid.12846","article-title":"Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus","volume":"20","author":"Devresse","year":"2018","journal-title":"Transpl Infect Dis."},{"key":"10.1111\/ajt.15480_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/OAJCT.S63058","article-title":"TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation","volume":"6","author":"Pascual","year":"2014","journal-title":"Open Access J Clin Trials."},{"issue":"3","key":"10.1111\/ajt.15480_bib24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/j.ajkd.2010.10.054","article-title":"The relationship between kidney function and long-term graft survival after kidney transplant","volume":"57","author":"Kasiske","year":"2011","journal-title":"Am J Kidney Dis."},{"issue":"7","key":"10.1111\/ajt.15480_bib25","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/ctr.12554","article-title":"Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival","volume":"29","author":"Srinivas","year":"2015","journal-title":"Clin Transplant."},{"issue":"7","key":"10.1111\/ajt.15480_bib26","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"10.1111\/ajt.15480_bib27","doi-asserted-by":"crossref","unstructured":"Tedesco-Silva H, Pascual J, Viklicky O, et al. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study. Transplantation. 2019; https:\/\/doi.org\/10.1097\/tp.0000000000002626 [Epub ahead of print].","DOI":"10.1097\/TP.0000000000002626"},{"issue":"1","key":"10.1111\/ajt.15480_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/TP.0000000000000869","article-title":"The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients","volume":"100","author":"O\u2019Leary","year":"2016","journal-title":"Transplantation."},{"issue":"9","key":"10.1111\/ajt.15480_bib29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/ctr.12418","article-title":"Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors","volume":"28","author":"Perbos","year":"2014","journal-title":"Clin Transplant."},{"issue":"6","key":"10.1111\/ajt.15480_bib30","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ndt\/gfx075","article-title":"Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial","volume":"32","author":"Budde","year":"2017","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"10.1111\/ajt.15480_bib31","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.15480_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.nefro.2016.11.007","article-title":"Recommendations for the use of everolimus in de novo kidney transplantation: false beliefs, myths and realities","volume":"37","author":"Pascual","year":"2017","journal-title":"Nefrologia."},{"issue":"4","key":"10.1111\/ajt.15480_bib33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.14504","article-title":"Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation","volume":"18","author":"Davis","year":"2018","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.15480_bib34","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1681\/ASN.2017030287","article-title":"Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development","volume":"28","author":"Wiebe","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"10.1111\/ajt.15480_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ctr.12045","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine","volume":"27","author":"Shihab","year":"2013","journal-title":"Clin Transplant."},{"issue":"4","key":"10.1111\/ajt.15480_bib36","doi-asserted-by":"crossref","first-page":"e12907","DOI":"10.1111\/tid.12907","article-title":"The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+\/R\u2212) kidney transplant recipients","volume":"20","author":"Cristelli","year":"2018","journal-title":"Transpl Infect Dis."},{"issue":"3","key":"10.1111\/ajt.15480_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.trre.2011.05.002","article-title":"The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen","volume":"26","author":"Suwelack","year":"2012","journal-title":"Transplant Rev (Orlando)."},{"issue":"3","key":"10.1111\/ajt.15480_bib38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1600-6143.2005.00742.x","article-title":"Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction","volume":"5","author":"Brennan","year":"2005","journal-title":"Am J Transplant."},{"issue":"7","key":"10.1111\/ajt.15480_bib39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMoa020439","article-title":"Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients","volume":"347","author":"Hirsch","year":"2002","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1111\/ajt.15480_bib40","doi-asserted-by":"crossref","first-page":"e12687","DOI":"10.1111\/tid.12687","article-title":"Incidence and outcome of BK polyomavirus infection in a multicenter randomized controlled trial with renal transplant patients receiving cyclosporine-, mycophenolate sodium-, or everolimus-based low-dose immunosuppressive therapy","volume":"19","author":"van Doesum","year":"2017","journal-title":"Transpl Infect Dis."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15480","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.15480","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522092942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522092942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:25:37Z","timestamp":1761629137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522092942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1600613522092942"],"URL":"https:\/\/doi.org\/10.1111\/ajt.15480","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.15480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}